CYP3A4 rs2242480: Pharmacogenomics and Drug Response
The rs2242480 variant is an intronic single nucleotide polymorphism located in the CYP3A4 gene, historically designated as the defining marker for the CYP3A4*1G allele. It has been investigated for its associations with altered clearance and variable response to medications such as tacrolimus, cyclosporine, and atorvastatin. However, the overall clinical evidence remains limited and complex due to strong genetic linkage with the nearby CYP3A5 gene.
What each genotype means
Typical baseline drug clearance
You have two copies of the common reference allele at this position, corresponding in literature to the standard CYP3A4*1 background. Research indicates normal baseline metabolism for CYP3A4-cleared medications such as fentanyl, tacrolimus, and certain statins, without the increased clearance or altered dose requirements sometimes seen with the variant allele. Because medication response depends on many clinical and genetic factors, discuss any dosing questions with your healthcare provider or pharmacist.
Carried by the majority of people worldwide, including approximately 90% or more of European and African populations and about 45% to 55% of East Asian populations.
Intermediate altered drug response
You carry one copy of the variant allele (historically designated CYP3A4*1G or *36 in star-allele nomenclature). Some studies, particularly in East Asian cohorts, correlate this genotype with altered clearance and dosing requirements for medications like fentanyl, cyclosporine, and tacrolimus, though research is mixed because of strong co-inheritance with CYP3A5*1. You should consult your clinician or pharmacist before considering any changes to medication regimens.
Carried by approximately 35% to 45% of individuals of East Asian ancestry and fewer than 10% of individuals of European or African descent.
Altered CYP3A-mediated drug clearance
You carry two copies of the variant allele (historically denoted as CYP3A4*1G/*1G or *36/*36). Clinical studies in East Asian populations associate this genotype with altered metabolism and dosing requirements for drugs like postoperative fentanyl, tacrolimus, and statins, although the exact mechanism remains partly confounded by high linkage disequilibrium with CYP3A5. Always review your prescriptions and discuss personalized dosing considerations with your physician or pharmacist.
Found in approximately 6% to 12% of East Asian populations, but observed in less than 1% of European or African populations.
Variant Details and Genomic Location
The single nucleotide polymorphism rs2242480 is located on chromosome 7 within intron 10 of the CYP3A4 gene. On the genomic forward reference strand, the variant typically manifests as a C to T transition (often reported on transcript sequences as c.1026+12G>A). Because it resides within an intron rather than a protein-coding exon, it does not directly alter the amino acid sequence of the enzyme. Instead, molecular studies suggest that rs2242480 sits in an epigenetic enhancer region that may modulate gene transcription or interact with nearby regulatory long non-coding RNAs such as AC069294.1. In pharmacogenetic literature, it was historically known as the defining single nucleotide polymorphism for the CYP3A4*1G allele, although pharmacogene nomenclature committees like PharmVar have continually updated and revised non-coding allele assignments. Understanding its non-coding nature helps explain why its biochemical effects are subtle rather than completely disrupting the enzyme.
The Role of CYP3A4 in Drug Metabolism
The CYP3A4 gene encodes Cytochrome P450 Family 3 Subfamily A Member 4, the most abundant and versatile drug-metabolizing enzyme in the human liver and small intestine. CYP3A4 is responsible for breaking down or bioactivating roughly 50% of all clinically prescribed medications. Its substrates span a wide variety of therapeutic classes, including immunosuppressive agents like tacrolimus and cyclosporine, HMG-CoA reductase inhibitors (statins) such as atorvastatin and simvastatin, synthetic opioids like fentanyl and sufentanil, calcium channel blockers, and chemotherapeutic agents. Because CYP3A4 sits at the central crossroads of human pharmacology, inherited variations that alter its expression or metabolic throughput can theoretically change systemic drug concentrations in the blood. Even small shifts in enzyme activity can influence therapeutic efficacy or elevate the risk of concentration-dependent adverse drug events.
Current Scientific Evidence and Clinical Complexities
The scientific evidence linking rs2242480 to altered drug clearance is categorized as limited and exhibits conflicting results across clinical studies. Early investigations in East Asian populations noted that carriers of the variant allele had faster clearance of tacrolimus, requiring higher doses to achieve target blood levels. However, rigorous genomic analyses showed that rs2242480 is in strong linkage disequilibrium with CYP3A5*1, a well-established functional allele that produces active CYP3A5 enzyme. Consequently, much of the observed clearance increase is attributable to CYP3A5 expression rather than rs2242480 itself. In contrast, other pharmacokinetic studies evaluating statins and opioids have linked rs2242480 to slightly lower hepatic CYP3A4 expression or altered metabolite ratios. Because these associations are modest and frequently confounded by neighboring genetic variants, expert groups like CPIC prioritize CYP3A5 genotyping over rs2242480.
Population Distribution and Ancestral Patterns
The frequency of rs2242480 varies significantly depending on geographic and genetic ancestry. The variant allele is common in East Asian populations, where reported allele frequencies generally range between 0.25 and 0.35. In contrast, it is observed at much lower frequencies in individuals of European and African descent, where the minor allele typically occurs in less than 5% of chromosomes. This marked divergence underscores the importance of ancestral context when evaluating pharmacogenetic findings. Because the variant often travels on the same ancestral haplotypes as other CYP3A family polymorphisms, clinical studies conducted exclusively in single populations may reflect unique linkage patterns that do not generalize across other global ancestries.
What This Information Means for Patients
Knowledge of an rs2242480 genotype provides valuable educational context about personal pharmacogenetic architecture, but it cannot be used in isolation to diagnose medical conditions or predict exact drug reactions. Clinical pharmacogenetic guidelines from organizations like CPIC and the Dutch Pharmacogenetics Working Group do not currently provide standalone dosing adjustments based solely on rs2242480. Drug metabolism is a multifactorial process governed by overall liver function, co-administered medications, diet, age, and broad multigene interactions. Individuals who review their genetic testing results should never initiate, discontinue, or alter prescription medications on their own. Any potential adjustments to medication regimens must be guided by a prescribing healthcare provider or clinical pharmacist in conjunction with therapeutic drug monitoring.
How common is this variant?
The variant allele is common in East Asian populations with an allele frequency of approximately 0.25 to 0.35, but it is substantially less frequent in European and African ancestries.
Frequently asked questions
Does having the CYP3A4 rs2242480 variant mean my medications will not work?
No, carrying this variant does not mean your medications will fail. While studies show small statistical differences in drug processing across populations, clinical outcomes depend on many genetic and environmental variables. Never alter your prescribed regimen without consulting your doctor.
What is the relationship between CYP3A4*1G and rs2242480?
The rs2242480 variant was historically the defining single nucleotide polymorphism for the CYP3A4*1G star allele. Recent updates by pharmacogene committees have revised these classifications, but older literature frequently uses these terms interchangeably.
Why is the evidence for rs2242480 considered limited?
Scientific evidence is considered limited because rs2242480 is closely linked to variants in the adjacent CYP3A5 gene, making it difficult to separate its direct effects from those of CYP3A5. Additionally, different pharmacokinetic studies have reported conflicting results regarding whether it increases or decreases enzyme activity.
Should I change my statin or immunosuppressant dose based on this SNP?
No, you should never adjust prescription medication dosing based on raw genetic data alone. Current clinical practice guidelines do not recommend specific dosage modifications based solely on rs2242480. Any questions about dosing or drug levels should be reviewed with your physician or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2242480?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP3A4
This variant is highly prevalent in populations of African and indigenous descent and is linked to increased rivaroxaban exposure and potential bleeding risk.
The CYP3A4*18 variant is significantly associated with the risk of anti-tuberculosis drug-induced hepatotoxicity, with effects modulated by pre-existing liver disease status.
CYP3A4 regulatory variant influencing transcription levels and downstream drug metabolism for various antineoplastics and immunosuppressants.
This SNP is associated with the activity of the major drug-metabolizing enzyme CYP3A4.
This variant defines the CYP3A4*20 allele, which is associated with a loss of function in the metabolism of various clinically important drugs.
The defining SNP for the CYP3A4*22 allele, which leads to significantly reduced metabolism of statins and immunosuppressants.